1. Home
  2. DECK vs CYTK Comparison

DECK vs CYTK Comparison

Compare DECK & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Deckers Outdoor Corporation

DECK

Deckers Outdoor Corporation

HOLD

Current Price

$78.00

Market Cap

12.4B

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$65.52

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DECK
CYTK
Founded
1973
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
10.7B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
DECK
CYTK
Price
$78.00
$65.52
Analyst Decision
Buy
Strong Buy
Analyst Count
23
19
Target Price
★ $122.45
$89.26
AVG Volume (30 Days)
★ 2.8M
1.6M
Earning Date
05-21-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 10.90
N/A
EPS
★ 0.94
N/A
Revenue
★ $5,472,296,000.00
$13,368,000.00
Revenue This Year
$11.16
$7.37
Revenue Next Year
$6.96
$310.19
P/E Ratio
$83.04
★ N/A
Revenue Growth
★ 9.76
N/A
52 Week Low
$77.37
$54.30
52 Week High
$122.29
$88.31

Technical Indicators

Market Signals
Indicator
DECK
CYTK
Relative Strength Index (RSI) 34.39 30.62
Support Level $77.37 $63.96
Resistance Level $83.00 $67.04
Average True Range (ATR) 2.05 2.20
MACD 0.40 -0.40
Stochastic Oscillator 12.24 3.37

Price Performance

Historical Comparison
DECK
CYTK

About DECK Deckers Outdoor Corporation

Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: